PHARMACOTHERAPY FOR ACUTE MANAGEMENT OF PULMONARY EMBOLISM

Azita H. Talasaz, PHARMD, PhD; Tara K. Lech, PHARMD; Adam Cuker, MD; Craig Beavers, PHARMD; Gregory Y.H. Lip, MD

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults outlines key recommendations for the management of acute PE. It emphasizes the use of low-molecular-weight heparin over unfractionated heparin and endorses direct oral anticoagulants for eligible patients. The guideline also addresses the management of cancer-associated venous thromboembolism and the need for refined risk stratification frameworks to guide treatment decisions.